Metabolic health

Stopping GLP-1 treatment: weight regain and continuing care

Stopping treatment is a clinical and practical decision, not simply removing an appetite effect. Follow-up should consider the reason for stopping, the original condition, and a plan for ongoing care.

Updated · Source-based editorial content · Medical review pending

A bowl of lentils and greens, an apple, a walking shoe, and an unlabelled capped sample tube.
Everyday health and the context around a blood test.
What to know: Weight regain was common in the STEP 1 extension, but a group average is not your destiny or evidence for one universal taper.

What the withdrawal study observed

In the STEP 1 extension, participants followed after withdrawal of semaglutide 2.4 mg and the study's lifestyle intervention regained about two-thirds of their prior weight loss over the following year on average. Many cardiometabolic improvements moved toward baseline.

The extension concerned a particular group and treatment setting. It does not establish the result for every medicine, every dose, a continued intensive lifestyle program, or every person who stops. Both medication and the study lifestyle intervention had ended, which matters when interpreting the finding.

Sources: STEP 1 extension: weight regain and cardiometabolic effects after semaglutide withdrawal

The reason for stopping changes the plan

Pregnancy planning, persistent adverse effects, insurance loss, a procedure, or a reassessment of benefit can require different actions. Semaglutide labels include a planned-pregnancy washout instruction; significant symptoms need timely care, not a delayed discussion about an optional taper.

If diabetes treatment is involved, the clinician may need to adjust other medicines or monitoring. Do not discontinue insulin or other diabetes therapies because a weight-management prescription is stopping.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information

Maintain follow-up and practical support

Ask what should be monitored, when to follow up, and which nutrition, activity, or other treatment supports are realistic. Continuing care can address weight trajectory and cardiometabolic risk without promising that one diet prevents all regain.

If cost is the reason, review coverage appeals or alternative approved pathways with the clinician. A low-cost research-use or unverified compounded offer is not a safe automatic replacement.

Sources: NIDDK: prescription medications to treat overweight and obesity · FDA concerns with unapproved GLP-1 drugs used for weight loss

Restarting is a separate prescribing decision

A former maintenance dose may not be tolerable after a long interruption. Follow the product-specific restart and escalation instructions with the prescriber, particularly after consecutive missed Wegovy injections.

The evidence does not identify one universal taper or restart protocol that fits every GLP-1 product. Keep the actual medicine, last dose, reason for stopping, and current symptoms available for the clinical discussion.

Sources: Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information · Zepbound prescribing information

Sources and evidence

Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.

  1. STEP 1 extension: weight regain and cardiometabolic effects after semaglutide withdrawal — Research
  2. Wegovy prescribing information, including tablets and Wegovy HD — Prescribing information
  3. Ozempic prescribing information — Prescribing information
  4. NIDDK: prescription medications to treat overweight and obesity — Clinical resource
  5. FDA concerns with unapproved GLP-1 drugs used for weight loss — Regulator
  6. Mounjaro prescribing information — Prescribing information
  7. Zepbound prescribing information — Prescribing information